Tempest Therapeutics, Inc. (TPST) stock
TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.33−0.01 (-4.24%)
Close on Nov 17, 2026Market cap $4.85MP/E –Yield –
Tempest Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tempest Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$40.64M. For fiscal 2025 it was -$26.58M. The highest annual figure on record is -$13.53M in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.58M | – |
| FY2024 | Dec 31, 2024 | -$42.03M | – |
| FY2023 | Dec 31, 2023 | -$29.16M | – |
| FY2022 | Dec 31, 2022 | -$34.64M | – |
| FY2021 | Dec 31, 2021 | -$26.99M | – |
| FY2020 | Dec 31, 2020 | -$19.30M | – |
| FY2019 | Dec 31, 2019 | -$45.40M | – |
| FY2018 | Dec 31, 2018 | -$26.87M | – |
| FY2017 | Dec 31, 2017 | -$84.33M | – |
| FY2016 | Dec 31, 2016 | -$81.01M | – |
| FY2015 | Dec 31, 2015 | -$72.00M | – |
| FY2014 | Dec 31, 2014 | -$47.93M | – |
| FY2013 | Dec 31, 2013 | -$29.13M | – |
| FY2012 | Dec 31, 2012 | -$13.53M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.72M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.59M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.74M | -242.4% |
| Q2 FY2021 | Jun 30, 2021 | -$6.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.27M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.43M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.24M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.14M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.83M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.75M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.16M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.69M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.81M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.99M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.39M | – |
| Q4 FY2017 | Dec 31, 2017 | -$42.40M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.59M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.37M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.96M | – |
See a number that looks wrong?